New Data Presented from Oncopeptides’ Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress

STOCKHOLM, June 16, 2019 /PRNewswire/ — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today updated interim efficacy and safety data from the ongoing, pivotal Phase 2 HORIZON trial. The oral presentation was included in the “Novel strategies in m…

New Data Presented at 24th EHA Congress From Oncopeptides’ Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM)

STOCKHOLM, June 14, 2019 /PRNewswire/ — Oncopeptides AB (Nasdaq Stockholm: ONCO), announced today new data presented at the 24th Congress of the European Hematology Association (EHA) in Amsterdam, including updated interim data from the ongoing phase …

New Data Presented at 24th EHA Congress From Oncopeptides’ Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM)

STOCKHOLM, June 14, 2019 /PRNewswire/ — Oncopeptides AB (Nasdaq Stockholm: ONCO), announced today new data presented at the 24th Congress of the European Hematology Association (EHA) in Amsterdam, including updated interim data from the ongoing phase …